A Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination with Carboplatin or Cisplatin + Pemetrexed Compared with Carboplatin or Cisplatin + Pemetrexed in Patients who are Chemotherapy-...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-003605-42

A Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination with Carboplatin or Cisplatin + Pemetrexed Compared with Carboplatin or Cisplatin + Pemetrexed in Patients who are Chemotherapy-Naive and have Stage IV Non-Squamous Non-Small Cell Lung Cancer

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

•To evaluate the efficacy of atezolizumab (atezo) as measured by investigator-assessed progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in atezolizumab + carboplatin + pemetrexed versus carboplatin + pemetrexed •To evaluate the efficacy of atezo as measured by overall survival (OS)


Critère d'inclusion

  • Non-squamous, Non-small cell lung cancer